During the last session, Travere Therapeutics Inc (NASDAQ:TVTX)’s traded shares were 2.03 million, with the beta value of the company hitting 0.72. At the end of the trading day, the stock’s price was $20.81, reflecting an intraday gain of 6.94% or $1.35. The 52-week high for the TVTX share is $20.33, that puts it up 2.31 from that peak though still a striking 75.4% gain since the share price plummeted to a 52-week low of $5.12. The company’s market capitalization is $1.81B, and the average intraday trading volume over the past 10 days was 1.29 million shares, and the average trade volume was 1.31 million shares over the past three months.
Travere Therapeutics Inc (TVTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. TVTX has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Travere Therapeutics Inc (TVTX) registered a 6.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.94% in intraday trading to $20.81, hitting a weekly high. The stock’s 5-day price performance is 15.16%, and it has moved by 19.60% in 30 days. Based on these gigs, the overall price performance for the year is 135.14%. The short interest in Travere Therapeutics Inc (NASDAQ:TVTX) is 8.72 million shares and it means that shorts have 7.07 day(s) to cover.
The consensus price target of analysts on Wall Street is $21.5, which implies an increase of 3.21% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $33 respectively. As a result, TVTX is trading at a discount of -58.58% off the target high and 42.34% off the low.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Statistics show that Travere Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Travere Therapeutics Inc (TVTX) shares have gone up 112.78% during the last six months, with a year-to-date growth rate more than the industry average at 22.68% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.34%. While earnings are projected to return -143.76% in 2025.
TVTX Dividends
Travere Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 7.5 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 9.6774% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $61.65 million.
Also, the Mutual Funds coming in first place with the largest holdings of Travere Therapeutics Inc (TVTX) shares are Delaware Group Equity Fds V-Small Cap Core Fund and Vanguard Total Stock Market Index Fund . Data provided on Aug 31, 2024 indicates that Delaware Group Equity Fds V-Small Cap Core Fund owns about 3.47 shares. This amounts to just over 4.45 percent of the company’s overall shares, with a $72.28 million market value. The same data shows that the other fund manager holds slightly less at 2.51, or about 3.21% of the stock, which is worth about $52.13 million.
